CFF-funded ICFTN training, MECFA MADI diagnostic donations, European CF registry participation, and Vertex free modulator access converge to bring comprehensive CF support to Pakistani patients for the first time. KARACHI / ISTANBUL / BOSTON — The Middle East Cystic Fibrosis Association (MECFA) and the Marmara University Cystic Fibrosis Center have completed a clinical assessment visit to the Indus Hospital and Health Network (IHHN) in Karachi, launching a structured CF capac

Researchers test a flexible sweat-sensing patch designed to make cystic fibrosis diagnosis more accessible. Editorial Illustration via AI By Lucia Carter About half the people with cystic fibrosis worldwide have never been diagnosed, by one widely cited estimate. Untreated, their life expectancy is under five years. In the United States, where the disease is caught early and treated, the projected median survival is 66 years. That gap is not primarily a knowledge problem. It

[8/21/2026] Today, the U.S. Food and Drug Administration published a new batch of draft product-specific guidances (PSGs) for developing generic drugs and generating evidence for abbreviated new drug applications (ANDAs). FDA publishes PSGs to help facilitate generic drug development, streamline ANDA assessment, and support greater access to generic drugs that are as safe and effective as their brand name counterparts and meet the same high-quality standards. Improving access

Study: Lung function in these patients tended to decline more during adolescence Written by Michela Luciano, PhD Developing cystic fibrosis (CF) during the first month of life may no longer necessarily predict poorer long-term outcomes, a new study from Portugal suggests. Despite experiencing substantial disease burden early in life, people whose signs of CF first manifested during the neonatal period had similar long-term nutritional outcomes and survival as those who did no

CAIRO - 15 August 2026: The Ministry of Health and Population announced that 792,592 newborns have been screened as part of the President's initiative for the early detection of genetic diseases, under the slogan “100 Million Healthy Lives,” since its launch on July 13, 2021. The initiative aims to build a healthy generation free from the causes of disability. Dr. Hossam Abdel Ghaffar, the Ministry's official spokesperson, explained that the initiative is currently in its

Developer Recode Therapeutics expects results by end of 2026 Written by Patricia Inácio, PhD A Phase 2a clinical trial testing RCT2100, Recode Therapeutics’ investigational inhaled mRNA therapy for cystic fibrosis (CF), is fully enrolled, with results expected by the end of the year, the company announced. The clinical updates were part of a broader company announcement focused on Recode’s CF programs, which also included new funding from the Cystic Fibrosis Foundation and a

Researchers will test gene-corrected airway cells and a biodegradable scaffold Written by Patricia Inácio, PhD The Cystic Fibrosis Foundation is funding a new research project that aims to develop a cell-based strategy for rebuilding damaged airway tissue in people with cystic fibrosis (CF). Do-Yeon Cho, MD, a professor in the Department of Otolaryngology–Head and Neck Surgery at the University of Alabama at Birmingham (UAB), received the Path to a Cure Pilot & Feasibility Aw

Still, individualized treatment approaches urged for patients Written by Marisa Horak, MS Use of Trikafta, an approved oral medication for cystic fibrosis (CF), can reduce airway inflammation — known to exacerbate symptoms — in people with the genetic disease, a new study demonstrates. However, after a year of treatment, CF patients on Trikafta still show differences in airway inflammation compared with what’s seen in people without CF, the researchers noted. The findings sug

Technology could pave way for faster, more precise, personalized treatment Written by Marisa Horak, MS Cutting-edge DNA sequencing technologies for microbial surveillance have the potential to revolutionize how lung infections in people with cystic fibrosis (CF) are diagnosed and managed, according to a new review study. However, researchers noted that there are still challenges that need to be overcome before these technologies can be adopted into widespread clinical tools.

Surgeons at Northwestern Memorial Hospital successfully transplanted a second set of lungs, a liver, and a kidney into a patient with cystic fibrosis and chronic organ rejection. RT’s Three Key Takeaways: Complex Lung Retransplantation: Surgeons successfully performed a second double-lung transplant alongside liver and kidney transplants for a patient with restrictive allograft syndrome. Machine Perfusion Technology: The use of advanced machine perfusion allowed the surgical